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ABSTRACT
Background: Standardized reporting of treatment-related adverse events (AE) is essential in clinical tri-
als, usually achieved by using the National Cancer Institute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE) reported by clinicians. Patient-reported adverse events (PRAE) may add value
to clinician assessments, providing patient perspective on subjective toxicity. We developed an online
patient symptom report and self-management system for real-time reporting and managing AE during
cancer treatment integrated with electronic patient records (eRAPID). As part of this program we devel-
oped a patient version of the CTCAE (version 4.0), rephrasing terminology into a self-report format. We
explored patient understanding of these items via cognitive interviews.
Material and method: Sixty patients (33 female, 27 male) undergoing treatment were purposively
sampled by age, gender and tumor group (median age 61.5, range 35–84, 12 breast, 12 gynecological,
13 colorectal, 12 lung and 11 renal). Twenty-one PRAE items were completed on a touch-screen com-
puter. Subsequent audio-recorded cognitive interviews and thematic analysis explored patients’ com-
prehension of items via verbal probing techniques during three interview rounds (n¼ 20 patients/
round).
Results: In total 33 item amendments were made; 29% related to question comprehension, 73%
response option and 3% order effects. These amendments to phrasing and language improved patient
understanding but maintained CTCAE grading and key medical information. Changes were endorsed
by members of a patient advisory group (N¼ 11).
Conclusion: Item adaptations resulted in a bank of consistently interpreted self-report AE items for use
in future research program. In-depth analysis of items through cognitive interviews is an important
step towards developing an internationally valid system for PRAE, thus improving patient safety and
experiences during cancer treatment.
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Patients receiving systemic cancer treatment can suffer
adverse events (AE) (symptoms and side effects), which
can compromise treatment plans, impair quality of life and
escalate to emergency hospital admissions [1]. Currently,
oncology treatment-related AE are assessed using the
National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0 [2].
Developed to standardize AE reporting in clinical trials, cri-
teria describe the severity of organ toxicity for patients
receiving cancer treatment. Toxicity is graded from mild
(Grade 1) through to life threatening (Grade 4). In routine
practice the CTCAE forms the basis for: (1) recommending
treatment modification or delay and use of supportive
medications; (2) standardizing documentation on the type
and severity of AEs; and (3) standardizing advice to oncol-
ogy clinicians and patients for the management of com-
mon AE [3].
CTCAE are designed to be reported by clinicians and
many can be objectively measured (e.g., deterioration of liver
function tests). However, 77 represent subjective symptoms
experienced by patients, which require the clinician first to
assess patient symptoms, then to assign an AE severity grade
(based on CTCAE descriptors) [4]. These subjective judge-
ments can lead to variations in reporting. Clinicians may
often underestimate symptom severity and not fully appreci-
ate patient priorities [5,6].
The importance of incorporating patients’ perspectives in
drug development and treatment evaluations has been
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increasingly recognized [7–10]. In 2005, the US Federal
drug agency issued detailed guidance on the use of
PROMs in drug trials, emphasizing that patient benefit from
a certain drug can only be claimed if this benefit is dem-
onstrated using PROMs. Similarly, the importance of PROMs
are recognized in the UK, where they have been collected
in the National Health Service (NHS) since April 2009 for
common elective surgical procedures, and by providers of
NHS-funded care [11]. Although AE are documented con-
sistently by physicians in clinical trials in routine care,
recording of AE by clinicians and reporting by patients is
variable and often omitted. The National Confidential
Enquiry into Patient Outcome and Death report noted the
inconsistent documentation of AE as an important factor in
the sub-optimal management of patients with significant
life-threatening chemotherapy toxicity, such as neutropenic
sepsis [1].
Accurate and comprehensive reporting of subjective AE
may be improved by asking patients to self-report their own
symptoms using validated instruments. If these do not pro-
vide sufficient symptom coverage of subjective AE, specially
adapted self-report versions can be employed. In a pioneer-
ing study, Basch et al. reworded CTCAE terminology (Version
3) into a patient-reported format [12] using the existing
descriptions for each severity grade. This straightforward
approach preserves at face value the CTCAE severity grading,
which has proven clinical utility. The resulting self-reported
AE items have proven acceptable to patients and have con-
cordance with clinician evaluated AE [5]. In a subsequent US
research program the NCI set out to create in a systematic
way a patient-reported measurement system, based on 77
identified subjective symptoms included in CTCAE v.4, known
as NCI patient-reported outcome (PRO)-CTCAE. For each AE
up to three patient-reported items were developed to indi-
vidually measure the frequency, severity, and/or interference
with activities [4,13]. This sound approach, based on meas-
urement science facilitates significantly patient self-reporting,
but it does not provide immediate mapping of the patient-
reported adverse events (PRAE) severity onto the CTCAE
severity grading. Further planned research by NCI will estab-
lish and validate severity thresholds for the patient-reported
items that correspond to the existing clinically relevant
CTCAE severity grades.
We set out to improve monitoring and managing of AEs
during routine cancer treatments by developing an online
system eRAPID (electronic patient self-Reporting of Adverse-
events: Patient Information and aDvice) allowing patients to
self-report and manage AE remotely in ‘real-time’ [14,15]. As
part of this research program, we adapted the current CTCAE
(Version 4.0) items for patient self-report using a similar
approach to Basch et al. [16], i.e., rephrasing the CTCAE into
patient language thus maintaining the content and the
established severity grading of AE. We chose this approach
rather than using the NCI PRO-CTCAE items, as for eRAPID it
was essential to use the CTCAE severity grades to guide the
development of a clinical algorithm to provide either self-
management advice for Grades 1–2 AE or alerts to patients
and clinicians for Grade 3 high severity AE and validation
data at that time was not available for the NCI PRO-CTCAE
items [13].
To confirm the validity of the newly adapted PRAE items,
we undertook cognitive interviews with patients receiving
treatment for a range of common cancers in the UK. We
aimed to explore the understanding, acceptability and clinical
meaningfulness of the new PRAE items. This manuscript
describes the first step in the eRAPID program, namely how
cognitive interviews were employed to evaluate the PRAE
items to ensure their accuracy and suitability for remote AE
monitoring in routine oncology practice.
Materials and method
Development of PRAE items
Fundamental to the success and safety of the program is
that the selected PRAE items are suited to frequent (weekly)
completion, consistently interpreted by patients and corres-
pond accurately to the CTCAE, as subsequent clinical man-
agement algorithms will be based on this system. To this
end, we explored developing items that matched the CTCAE
with one question and one response format (descriptors cor-
responding to severity grades) for the eRAPID symptom
report questionnaire.
In total 16 of the most common treatment-related AE
were identified from a review of clinical trials literature, AE
reported on reputable UK cancer advice websites and PRAE
from a databank of 1500 previously recorded and content-
analyzed clinical consultations [16]. AE were ranked for com-
monality within and between five common cancer groups
(Breast, Lung, Colorectal, Gynecological and Renal) including:
nausea, mucositis, nose bleeds, vomiting, palmar-plantar ery-
thema (PPE), chills, pain, loss of appetite, flu-like symptoms,
diarrhea/increased stoma activity, insomnia, rash, fatigue,
constipation, peripheral neuropathy, dyspnea and thrombo-
cytic purpura. A further three item areas were added after
consultation with clinical and patient representatives: depres-
sion, anxiety and a patient-reported version of the Eastern
Cooperative Oncology Group (ECOG) performance status [17]
along with a question on stoma activity (21 in total).We
developed a set of core PRAE items mapping directly onto
CTCAE version 4 (see Table 1). The suitability of the PRAE
Table 1. Example of the rewording of the CTCAE grading into a PRAE item (nausea).
CTCAE Version 4.0 PRAE item
Nausea Have you felt sick (nauseous)?
0. No
1. Loss of appetite without alteration in eating habits 1. I felt a bit sick but I was able to eat and drink as usual
2. Oral intake decreased without significant weight loss, dehydration or malnutrition 2. I felt quite sick and I ate or drank less than usual
3. Inadequate oral caloric or fluid intake, tube feeding, TPN, or hospitalization indicated 3. I felt very sick and was not able to eat or drink
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items for clinical practice was endorsed by clinicians via inter-
view [16].
Recruitment
Patients were purposively sampled by age, gender and tumor
group (to capture a range of tumor sites and toxicity) and
recruited from the outpatient, day case unit and the acute
admission unit at the Institute of Oncology at St James’s
University Hospital, Leeds, UK. Patients were eligible if they
had breast, lung, renal and colorectal cancer, were under-
going chemotherapy or biological treatment with curative or
palliative intent, could read and understand English and in
opinion of their care team did not exhibit overt psychopath-
ology or serious cognitive dysfunction. Patients were intro-
duced to the researchers by their direct clinical team. Written
informed consent was then obtained. Ethical approval was
granted from Leeds East Ethics Committee on 07/06/2011
(REC ref: 11/YH/0159).
Cognitive interviews
For some of the AEs, our approach resulted in complex
descriptions of the frequency, severity and impact of
symptoms if compared with simpler response options
used in symptom or quality of life questionnaires (Have
you had pain? Not at all, a little, quite a bit, very much).
It was important to explore how patients would respond
to these items. Cognitive interviews are established meth-
odology for pretesting questionnaires to establish patient
understanding [18]. Typically verbal probing techniques
are used to explore participants’ cognitive processes [18].
The technique has proven utility in pretesting question-
naires in clinical and health research and is particularly
effective in helping to delineate complex ideas and con-
cepts [19].
Pilot interview
Prior to the study interviews we piloted the technique with a
single female breast cancer patient advocate (SK). This
enabled us to refine the interview method and determine
the timing and wording of cognitive probes and the level of
patient burden when completing the questionnaire.
Procedure
During a six-month period patients completed PRAE (n¼ 21
items) alongside NCI PRO-CTCAE items (n¼ 56). Results from
the cognitive interviews on NCI PRO-CTCAE items will be
reported separately. The PRAE and NCI PRO-CTCAE items
were presented alternately to all patients on a computer on
a single occasion in a private area in the oncology outpatient
clinic, the day case unit or the acute oncology admissions
unit at St James’s University Hospital, Leeds, UK. Participants
were observed by a researcher whilst completing items, and
asked to think aloud whilst answering. The researcher noted
where patients experienced difficulty (e.g., understanding
questions or choosing a response). Subsequently, patients
took part in an audio-recorded interview and were retro-
spectively verbally probed (see Figure 1) on items where
they had reported difficulty. Probes were determined a priori
based on common sources of error in survey questions [18].
Interviews were transcribed verbatim and managed in NViVO
software version 9.
Concordant with recommended cognitive interview pro-
cedure, iterative rounds of testing were employed [18–20].
To increase the generalizability of the adaptations made to
items, 20 different patients completed all the items in three
rounds of testing (60 in total). Based on the feedback,
changes to items were put forward to subsequent rounds. By
the final round we concluded that saturation was reached
because changes were minimal [21]. Patient partners from
our patient advisory group (N¼ 11) endorsed the final
changes.
Analysis
Interviews were transcribed verbatim and managed in NViVO
software (version 9). In addition, all patient responses to AE
items were transferred into SPSS, and the percentage of
patients having difficulty with each item was computed.
Initially patients’ views on items were coded under the corre-
sponding AE, e.g., nausea, pain, chills. Issues related to
understanding of questions and suggestions for alternative
wording were then sub-coded into the themes of question
comprehension and difficulties with selecting a response were
coded under response option. Where patients intimated that
they may have answered differently had the question been
preceded or succeeded by another, this was coded as order
effects.
A consensus-based approach to item modification was
adopted to avoid false problem identification by using one
Q. Have you felt sick
(nauseous)?
0. No
1. I felt a bit sick but I
was able to eat and
drink as usual
2. I felt quite sick and I
ate or drank less than
usual
3. I felt very sick and
was not able to eat or
drink
Cognive probes
Are there any other words/phrases
you would use to describe nausea?
Was it easy to choose an answer?
What made x beer than y?
What does a
bit/quite/very sick
mean to you?
Would you term it ‘as
usual’ if you ate
something diﬀerent?
Does this mean not
being able to eat at all
or limited intake?
Nausea item
Figure 1. Examples of cognitive probes used to explore patient understanding
of PRAE item (nausea).
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researcher alone [22–24]. Modifications were therefore made
by two researchers PH & LW and a clinician GV; some items
were referred to the eRAPID project management team, clin-
ical team and patient advisory group. Item revision was dis-
cussed after each round in view of suggestions answers/
comments from patients by reviewing: 1) audio recordings;
2) researcher notes; and 3) the percentage of patients who
identified problems with the item. An item tracking matrix
[19] was developed showing the item content, changes
made and supportive quotes (Table 2). Preserving congru-
ence with CTCAE criteria was an important consideration
when amending items.
Results
Participants
In total 107 patients were approached, 19 declined, 20
became ineligible (e.g., finished treatment or died), and eight
were missed (e.g., discharged before taking part). Sixty
patients (33 female, 27 male) undergoing biological and
chemotherapy were recruited (median age 61.5, range 35–84,
12 breast, 12 gynecological, 13 colorectal, 12 lung and 11
renal) see Table 3 for detail. Twenty (34%) of the patients
had basic compulsory school education, 17 (28%) had
continued education (e.g., apprenticeship, vocational qualifi-
cations) and 23 (38%) had a higher university degree.
Item change
The percentage of patients expressing a problem with items
was on average 36% (ranging from 6–100%, i.e., all patients
having a problem). Sometimes, item amendments were initi-
ated when as few as one patient expressed a problem, e.g.,
one patient suggested to us how incorrect information could
have been elicited from the question ‘Have you increased the
number of times you have had to change your stoma bag?’
and that ‘emptying’ is a more appropriate term as patients
do not ‘change’ their bags every time they have a bowel
movement. This served as a reminder that frequency of
occurrence is not always indicative of the magnitude of the
problem [18]. In cases where only a few patients had diffi-
culty, we sought advice from the clinical team and patient
advocates. An illustration of the iterative process in adapting
the items is illustrated in Table 2 for the pain PRAE item.
Question comprehension modifications
The majority of items, including pain, nausea, stoma activity,
diarrhea and fatigue, were modified to the satisfaction of par-
ticipants following one or two amendments, e.g., adding
Table 2. The Tracking matrix for PRAE pain item, CTCAE grading V 4.0, cognitive probes, supporting quotes and changes made by round.
CTCAE V 4.0 (pain) PRAE original litem Changes made to item and supporting quotes
Item post-cognitive
interview
Round 1 (n¼ 20) Round 2 (n¼ 20) Round 3 (n¼ 20)
Q. Have you had pain? Comprehension Comprehension No changes made Q. Have you had pain or
discomfort anywhere on
your body?
0. No Patients x6 thought they
only had to report cancer-
related pain
Patients x2 could not
endorse the term pain
but labeled it
discomfort
0. No
1. Mild pain
2. Moderate pain, limiting
instrumental ADL
3. Severe pain, limiting
self-care ADL
1. I had mild pain
2. I had moderate pain
and I was not able to
do some of the things
I normally do (e.g.,
household chores)
3. I had severe pain and
I was not able to carry
out daily activities
Examples of quotes
‘Is it pain because of the
treatment or just normal
pain like backache or. . .?’
p5
‘Yes, you see my answer to
that has nothing to do
with chemo, it’s the
aftermath of the DVT.
. . ..Well actually if we're
still talking about the
chemo, then that should
be none, shouldn't it? So
we should change that’
p2 what tumor group
and age?
Examples of quotes
‘Ok that word pain and
my expression of dis-
comfort’
R: Do you prefer to call it
discomfort?
‘I do when they ask me
things yes. How often
do you have pain
around your body? It’ll
have to be rarely
because I can’t define
what pain is. I mean
erm drilling your teeth
is painful isn’t it? But
you can have a needle
that’s very quickly pain-
ful but they’re two dif-
ferent intensities.’
R: So if we said it was dis-
comfort what would
you say to that?
‘Yes, yes’ p39
1. I had mild pain or dis-
comfort
2. I had moderate pain or
discomfort and I was
not able to do some of
the things I normally
do (e.g., household
chores/shopping*)
3. I had severe pain or
discomfort and I was
not able to take care of
myself (getting out of
bed, bathing,
dressing†)
Added
Anywhere on your body
Added
Discomfort
ADL: activities of daily living; R: researcher.
*denotes addition of shopping general change to clarify instrumental ADL; †descriptors to clarify self-care ADL.
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‘any’ as a prefix to ‘have you had pain’. Other notable find-
ings include 15% of patients in Round 1 who misunderstood
nausea as, for example ‘feeling dizzy’ leading to the addition
of the suggested descriptors ‘(feeling sick and queasy)’ to aid
understanding. Following the changes made, no problems
were expressed by patients discussing this item in subse-
quent rounds. Two patients understood chills to mean
‘feeling cold’ rather than experiencing symptoms of infection
therefore the descriptors ‘(shivering, shaking, chattering of
teeth)’ were added as a suffix (thus maintaining congruity
with CTCAE grading). However, in further rounds the word
‘chills’ was dropped from the question as it continued to be
misunderstood by 10% of patients. The descriptor ‘achy’ was
added to ‘hot, cold and shivery’ to aid the understanding of
‘flu-like symptoms’, and the descriptor ‘loose’ was added to
describe diarrhea. Further, it became clear patients could not
make the distinction between ‘aging spots’ and a ‘purpuric
rash’ in the description of thrombocytic purpura. Therefore, it
was eventually decided that we would have to consider
using an image. Overall, 14 modifications related to question
comprehension were made (for details see Table 4 of the
online supplementary material). Depression and anxiety items
were generally understandable to patients, however, clini-
cians suggested the removal of the prefix ‘in the past two
weeks’ as although a useful time frame for diagnostic pur-
poses, it was thought redundant and confusing for weekly
home self-report. The peripheral neuropathy item was also
adapted by clinicians from tingling in ‘hands and feet’ to tin-
gling in ‘fingers and toes’.
Response option modifications
The majority of response options required minor amend-
ments and were consistently interpreted by patients by the
final round (e.g., mucositis, depression, constipation, nose
bleeds, anxiety, peripheral neuropathy and chills). Following
patient recommendation for the diarrhea item, two response
options were merged, based on the similarity of descriptors,
e.g., ‘incontinence’ and ‘bowel opening’ seven times a day.
Other items needed further modification to ensure con-
sistent patient interpretation, e.g., for nausea we inserted ‘the
same amount and type of food’ into the response option to
accommodate patients who answered they ‘ate and drank as
usual’, but when probed actually changed what they ate or
drank. Further, the quantifiers (e.g., a bit, quite and very)
were removed from the nausea item after patients found it
difficult to respond to both (1) interference and (2) quantity
factors (e.g., ‘I felt a bit sick but could not eat and drink nor-
mally’). These amendments ensured closer congruence with
the CTCAE. The appetite response options ‘ate and drank less
than usual’ and ‘took supplement drinks’, were amalgamated
as both response options applied to many patients experi-
encing a reduced appetite. Despite modification to the skin
rash item responses, patients were persistently confused by
the complexity of the text and multiple factors (e.g., itching/
pain/oozing and peeling) resulting in the adaptation of the
question to incorporate these multiple factors rather than
the response option (see Table 5 of the online supplemen-
tary material). Patients had difficulty choosing a response for
the palmer-plantar erythema item so further descriptors were
introduced and the word ‘not’ emboldened to emphasize the
distinction between ‘painful’ and ‘not painful’ required by the
CTCAE. A similar emboldening of the word ‘was’ and ‘was
not’ was employed to assess whether rest relieved fatigue.
Researchers also amended the constipation item to include
more patient friendly language, e.g., changing ‘I have modi-
fied my diet’ to ‘I have changed my diet’.
Patient-reported descriptors matching the CTCAE instru-
mental (preparing meals/shopping) and self-care activities of
daily living (ADL; bathing and feeding) were added to a num-
ber of PRAE items (fatigue, flu-like symptoms, breathing,
depression, anxiety and PPE). We added ‘shopping’ to ‘things
I normally do’ and replaced ‘not able to carry out daily
activities’ with ‘not able to take care of myself’.
Order effects
We reordered the item ‘Have you had shivering or shaking
chills?’ to follow ‘Have you had flu-like symptoms?’, as a num-
ber of patients believed that ‘chills’ referred to being cold
Table 3. Patient characteristics for overall sample (N¼ 60) and by round
(n¼ 20).
Overall sample (N¼ 60) Round 1 Round 2 Round 3
Age
Mean 59.6, (SD 12) 59.05 (11.5) 61.35 (13.6) 58.25 (11.5)
Range 35–84 39–76 41–84 35–77
Gender (n)
Female: 33, Male: 27 F: 15, M: 5 F: 13, M: 7 F: 5, M: 15
Months since diagnosis
Mean 24.6 (SD: 36) 31.91 (48) 21.65 (30) 20.35 (28)
Range 3–164 0–164 2–84 1–111
Days since last treatment
Mean 10.1 (SD: 13) 7.45 (10) 14.35 (17) 8.40 (11)
Range 0–62 0–34 0–62 0–38
Tumor group (n)
Breast 12 7 3 2
Gynecological 12 3 6 3
Renal 11 1 4 6
Lung 12 6 4 2
Colorectal 13 3 3 7
Recruitment site (n)
Acute 14 5 8 1
Daycase/OPD 46 15 12 19
Treatment (n)
Chemotherapy 49 19 16 14
Biological therapy 11 1 4 6
Metastases (n)
None 28 7 9 12
In 1 area 21 10 4 7
>1 area 11 3 7 1
Education
Basic compulsory school
education only
20 10 8 2
Beyond basic school
(e.g., vocational qualifications)
17 3 7 7
University degree or equivalent 23 7 5 11
Employment (n) 9 3 2 4
Full time 8 4 4 0
Part time 10 0 4 6
Illness/disability 31 13 9 9
Retired 1 0 0 1
Unemployed 1 0 1 0
Other
Social support (n)
Married 32 7 11 14
Cohabiting 6 2 1 3
Separated 13 7 5 1
Widowed 6 2 3 1
Single 3 2 0 1
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rather than a serious infection with temperature. The order
change was designed to ensure a stronger association
between flu-like symptoms and chills.
Overall 33 amendments were made to the items, with the
majority made in Round 1 (n¼ 17), and Rounds 2 and 3
yielding n¼ 10 and n¼ 7, respectively.
Discussion
Cognitive interviews were employed to pretest the content
and acceptability of items to report AE in oncology patients
undergoing treatment for a range of common cancers.
Generally, the items presented to patients were interpreted
consistently. However, the interviews uncovered a number of
important issues in patient understanding and responses,
and modifications were made accordingly. When adapting
items, we endeavored to refine items to facilitate patient
understanding, whilst maintaining the clinical applicability to
reflect the CTCAE.
Modifications included asking patients to report any pain
(not just cancer-related pain) and adding an additional
‘discomfort’ as a descriptor to accommodate patients who
could not endorse ‘pain’ as a concept. To aid comprehension,
‘feeling sick and queasy’ was added to nausea items.
In line with previous research, additional descriptors were
included, in this case for items relating to anxiety, incontin-
ence, flu and chills (the latter seemingly a cultural idiom
which could not be embraced by UK patients). Additional or
alternative descriptors are in line with adaptations made to
the NCI PRO-CTCAE items during the cognitive interview pro-
cess [4] with parentheses generally used to convey any add-
itional contextual information. Another challenge when
developing the items was reflecting the impact and interfer-
ence on activities of daily living. The CTCAE reports these
only for severe AEs whereas we had to adapt this general
statement to the context of the item and use different
descriptions.
Adapting the response options posed a greater challenge
due to the need to represent the multiple attributes of the
CTCAE (e.g., frequency, severity and interference). The major-
ity of changes were made to items where symptom-specific
information was required (e.g., eating habits). Also problem-
atic was how to describe the CTCAE instrumental and
self-care ADL. The level of interference with self-care and
instrumental activities in these response options was particu-
larly challenging, e.g., fatigue, PPE and skin rash. These items
were fundamentally modified to accommodate the informa-
tion required to align with the CTCAE, supporting previous
studies where descriptions of daily living were misinterpreted
[4]. This may have reflected cultural differences in interpret-
ation (the CTCAE originates from the US). We strongly recom-
mend that questionnaires be pretested using cognitive
interviews as there appear to be subtle differences which
affect understanding, even among native English speakers.
For example, it appeared that our sample of English patients
did not have the same understanding of the word ‘chills’.
It is a known phenomenon that the order of presentation
of questionnaire items can influence how they are answered
[22]. Indeed, our findings indicated that similar items have to
be mindfully presented to avoid influencing response
selection.
We purposively sampled oncology patients by tumor
group, age and gender to maximize the generalizability of
the findings with the future goal of establishing an under-
standing of AE items across a range of common cancers for
remote self-report. To further allow generalizability, we
adopted an approach of presenting the items to a new set
of patients in each round, rather than presenting to the
same patients again. In essence, we took an exploratory [18]
rather than a confirmatory approach to ascertain new
insights/uncover new problems. With this approach, there is
a risk that novel problems will continue to be unearthed.
However, by the final round saturation was reached, as we
were not discovering any new problems [21], and amend-
ments were minimal. As others have suggested, it would be
useful to engage in a dialog with those in the field to work
towards an agreed best practice in cognitive interviewing
[20,23,24]. Certainly, a balance must be achieved in terms of
an exploratory or confirmatory approach to ensure that as
many comprehension issues as possible are addressed, with-
out focusing on irrelevant minutiae.
The findings from the cognitive interviews have resulted
in a bank of items reviewed for clinical meaningfulness and
face validity in a group of patients with common cancers in
the UK. The items are a succinct measure of interference/
severity of AE whilst avoiding asking multiple attributes of
each item. For our online adverse reporting and manage-
ment system eRAPID, the responses from the PRAE item
would form the basis of the algorithmic questionnaire scor-
ing. We developed each PRAE item by re-wording the CTCAE
criteria into patient language and each response option cor-
responded directly to the severity grading of CTCAE (Grades
0–3). The algorithms linking the AE severity to appropriate
levels of advice were developed in consultation with clinician
and patient representatives from each tumor group. For
severe symptoms (Grade 3 AE) or a combination of several
medically significant Grade 2 responses patients would be
advised to telephone the hospital immediately and a clinician
would be alerted. For Grade 1 response patients would be
given self-management advice and for Grade 2 patients
would advised to self-manage, but asked to mention their
symptoms at the next hospital visit.
The necessary adaptations highlight the value of conduct-
ing pretests of items via cognitive interviews with patients
and adapting them via discussion with the clinical team.
Clearly, it is wrong to assume a common understanding [19]
of item content across all respondents and pretesting items
in this way may impact on the quality and ultimately the
consequences of PRO reporting. It is possible that the educa-
tional level of participants may have influenced the under-
standing of items. Over a third of our sample had an
education to a higher degree in comparison with an average
of 25% figure for the general UK adult population in our area
in 2011 [25]. This may have had a bearing on the level of
engagement with the study and eager suggestions for the
alternative wording of items.
The bank of items was included in an eRAPID usability
study with adjuvant breast cancer patients. Prior to this
6 P. HOLCH ET AL.
oncologists and clinical nurse specialists had recommended
adjustments. Generally, these changes were based on con-
textual considerations, e.g., time period for reporting, priori-
tization of questions (as essential) for different tumor groups
(leaving other questions optional), and addition of a yes/no
prefix. Although cognitive interviewing is an excellent way to
check patient understanding of items, we suggest that
researchers liaise with staff to check their understanding to
situate their findings in a clinical perspective and in view of
local treatment regimens. A full clinical validation of the
items is now underway in a pilot study in common cancer
groups undergoing systemic therapy.
In conclusion, cognitive interviews are a useful tool to pre-
test questions to allow adaptation prior to administration to
ensure consistency in patient understanding. Pretesting of
toxicity items in this way makes a necessary contribution
towards developing a clinically relevant system for PRAE
both in clinical trials and patient care thus improving patient
safety and experiences during cancer treatment.
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